<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196273</url>
  </required_header>
  <id_info>
    <org_study_id>09-4085</org_study_id>
    <nct_id>NCT01196273</nct_id>
  </id_info>
  <brief_title>Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follow-up</brief_title>
  <official_title>HIV-HEART STUDY: A Prospective, Epidemiologic and Multicentre Trial to Determine the Cardiovascular Risk in HIV-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HIV-HEART Study Investigative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Heart Failure Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Competence Network for HIV/AIDS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV-infection is associated not only with a reduced function of the immune system, but also
      linked with diseases of other organ systems, in particular with the heart.

      Heart conditions that have been described with HIV include

        -  Pericarditis,

        -  Pleural effusion

        -  Pulmonary hypertension (Venedic classification typ II)

        -  Dilated cardiomyopathy

        -  Heart failure

        -  Myocarditis

        -  Bacterial endocarditis

        -  Heart valve disorders In addition to previously stated disorders of the heart, the
           premature atherosclerosis of coronary arteries, a further even more important disease of
           the heart in this patient population, went into the focus of most HIV-researchers and
           physicians.

      Premature atherosclerosis of coronary arteries results in coronary calcification, angina
      pectoris, myocardial infarction and sudden death. HIV-positive patients are at greater risk
      for a variety of heart-related conditions, including coronary artery disease. It is assumed,
      that HIV infection doubles the risk of a heart attack, according to recent research.

      The reason for this link between HIV and heart-related conditions is unknown, but secondary
      infections that affect the heart muscle and coronary arteries have a greater chance of
      occurring in people with compromised immune systems. In addition, the HI-virus itself had
      been detected in the myocardium and might have an impact on the premature of cardiovascular
      diseases.

      Furthermore, some of the medications used to treat HIV patients (antiretroviral therapy, ART)
      are assumed to have heart-related side effects.

      Therefore, current treatment regimens for HIV infection have to be balanced against the
      marked benefits of antiretroviral treatment. Nevertheless, prevention of coronary heart
      disease should be integrated into current treatment procedures of HIV-infected patients.

      The link between the heart and HIV is well established but not well understood. Therefore,
      further results are needed for efficient guidelines for the prevention, diagnostic and
      therapy of HIV-associated cardiovascular diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A comprehensive detailed description of the study procedures had been previously published
      (European Journal of medical research 2007;12:243-248).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular Diseases in HIV-infected Patients</measure>
    <time_frame>Baseline up to 5 years follow-up</time_frame>
    <description>The detection of prevalence, aetiology, progression and severity of cardiovascular diseases - especially of coronary artery disease - in HIV-infected patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Disorders in HIV-infected Patients HIV-HEART</measure>
    <time_frame>Baseline up to 5 years follow-up</time_frame>
    <description>The study also investigates the impact of established risk factors and new HIV-specific risk factors of coronary artery disease such as, age, gender, virus-load, CD4-cell count. The HIV-HEART study will focus on the impact of medication including cardiovascular medication and antiretroviral medication. Further secondary objectives will be examined, including economic costs and quality of life of subjects with and without cardiovascular diseases in this patient population.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1424</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Heart Failure</condition>
  <condition>HIV</condition>
  <condition>AIDS</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Regional Ruhrgebiets Cohort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comprehensive non invasive cardiovascular examination</intervention_name>
    <description>The examination includes:
Anamnesis incl. admission form
Physical examination
Documentation of the medical therapy (incl. HAART)
Electrocardiogram
Transthoracic echocardiography
Exercise electrocardiogram
6 minute walk test
Blood collection
Questionnaire to quality of life and health economics</description>
    <arm_group_label>Regional Ruhrgebiets Cohort</arm_group_label>
    <other_name>The examination includes:</other_name>
    <other_name>- Anamnesis incl. admission form</other_name>
    <other_name>Physical examination</other_name>
    <other_name>Documentation of the medical therapy (incl. HAART)</other_name>
    <other_name>Electrocardiogram</other_name>
    <other_name>Transthoracic echocardiography</other_name>
    <other_name>Exercise electrocardiogram</other_name>
    <other_name>6 minute walk test</other_name>
    <other_name>Blood collection</other_name>
    <other_name>Questionnaire to quality of life and health economics</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stored blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population included outpatients who were at least 18 years of age, had a known
        HIV-infection and exhibited a stable disease status within 4 weeks before inclusion of the
        trial. Written informed consent was obtained from all participants.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Known HIV-infection

          -  Written informed consent

        Exclusion Criteria:

          -  Acute cardiovascular disease

          -  Unstable hemodynamic status in the three weeks before inclusion

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Esser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Till Neumann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Bochum, Department of Dermatology</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV Outpatient Department</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Dermatology and Venerology</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, West German Heart Center Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Coordinating Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Neumann T. [HIV, AIDS and the cardiovascular risk]. Internist (Berl). 2008 Apr;49(4):429-30, 432-5. doi: 10.1007/s00108-008-2049-4. Review. German.</citation>
    <PMID>18305915</PMID>
  </results_reference>
  <results_reference>
    <citation>Reinsch N, Buhr C, Krings P, Kaelsch H, Kahlert P, Konorza T, Neumann T, Erbel R; Competence Network of Heart Failure. Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: results of the HIV-HEART Study. HIV Med. 2008 Aug;9(7):550-6. doi: 10.1111/j.1468-1293.2008.00602.x. Epub 2008 Jun 28.</citation>
    <PMID>18557952</PMID>
  </results_reference>
  <results_reference>
    <citation>Reinsch N, Buhr C, Krings P, Kaelsch H, Neuhaus K, Wieneke H, Erbel R, Neumann T; German Heart Failure Network. Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials. 2009 Jul-Aug;10(4):261-8. doi: 10.1310/hct1004-261.</citation>
    <PMID>19723613</PMID>
  </results_reference>
  <results_reference>
    <citation>Neumann T, Reinsch N, Neuhaus K, Brockmeyer N, Potthoff A, Esser S, Hower M, Neumann A, Mostardt S, Gelbrich G, Erbel R; für die HIV-HEART-Studie sowie die Kompetenznetze Herzinsuffizienz und HIV/AIDS. [BNP in HIV-infected patients]. Herz. 2009 Dec;34(8):634-40. doi: 10.1007/s00059-009-3313-7. German.</citation>
    <PMID>20024643</PMID>
  </results_reference>
  <results_reference>
    <citation>Neumann T, Esser S, Potthoff A, Pankuweit S, Neumann A, Breuckmann F, Neuhaus K, Kondratieva J, Buck T, Müller-Tasch T, Wachter R, Prettin C, Gelbrich G, Herzog W, Pieske B, Rauchhaus M, Löffler M, Maisch B, Mügge A, Wasem J, Gerken G, Brockmeyer NH, Erbel R; HIV-HEART Study Investigative Group. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. Eur J Med Res. 2007 Jun 27;12(6):243-8.</citation>
    <PMID>17666313</PMID>
  </results_reference>
  <results_reference>
    <citation>Breuckmann F, Neumann T, Kondratieva J, Wieneke H, Ross B, Nassenstein K, Barkhausen J, Kreuter A, Brockmeyer N, Erbel R. Dilated cardiomyopathy in two adult human immunodeficiency positive (HIV+) patients possibly related to highly active antiretroviral therapy (HAART). Eur J Med Res. 2005 Sep 12;10(9):395-9.</citation>
    <PMID>16183552</PMID>
  </results_reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. med. Till Neumann MD, Dr. med. Stefan Esser MD</name_title>
    <organization>University Hospital</organization>
  </responsible_party>
  <keyword>Cardiac Diseases,</keyword>
  <keyword>HIV-Infection,</keyword>
  <keyword>AIDS,</keyword>
  <keyword>Antiretroviral Therapy,</keyword>
  <keyword>Cardiovascular Medication,</keyword>
  <keyword>Risk Factors,</keyword>
  <keyword>coronary heart disease,</keyword>
  <keyword>heart failure,</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

